| . |  |
. |
| . | |
. |
 by Staff Writers Sydney, Australia (SPX) Mar 09, 2022
A new DNA test, developed by researchers at the Garvan Institute of Medical Research in Sydney and collaborators from Australia, UK and Israel, has been shown to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more-accurately than existing tests. 'We correctly diagnosed all patients with conditions that were already known, including Huntington's disease, fragile X syndrome, hereditary cerebellar ataxias, myotonic dystrophies, myoclonic epilepsies, motor neuron disease and more,' says Dr Ira Deveson, Head of Genomics Technologies at the Garvan Institute and senior author of the study. The diseases covered by the test belong to a class of over 50 diseases caused by unusually-long repetitive DNA sequences in a person's genes - known as 'Short Tandem Repeat (STR) expansion disorders'. 'They are often difficult to diagnose due to the complex symptoms that patients present with, the challenging nature of these repetitive sequences, and limitations of existing genetic testing methods,' says Dr Deveson. The study, published in Science Advances , shows that the test is accurate, and allows the team to begin validations to make the test available in pathology services around the world. A patient who participated in the study, John, first realised something wrong when he experienced unusual problems balancing during a ski lesson. 'It was very worrying having symptoms that, over the years, increased in severity; from being active and mobile to not being able to walk without support. I had test after test for over ten years and absolutely no answers as to what was wrong,' says John, who was eventually diagnosed with a rare genetic disease called CANVAS, which affects the brain. 'It was reassuring to finally confirm my diagnosis genetically, and it's exciting to know that, in the near future, others with these types of conditions will be able to get a diagnosis quicker than I did,' he says. 'For patients like John, the new test will be a game-changer, helping to end what can often be a taxing diagnostic odyssey,' says Dr Kishore Kumar, a co-author of the study and neurologist at Concord Hospital and the University of Sydney, and visiting scientist at the Garvan Institute. Repeat expansion disorders can be passed on through families, can be life threatening and generally involve muscle and nerve damage, as well as other complications throughout the body.
Quicker, more-accurate diagnosis for patients avoids 'diagnostic odyssey' 'This new test will completely revolutionise how we diagnose these diseases, since we can now test for all the disorders at once with a single DNA test and give a clear genetic diagnosis, helping patients avoid years of unnecessary muscle or nerve biopsies for diseases they don't have, or risky treatments that suppress their immune system,' says Dr Kumar. Although repeat expansion disorders cannot be cured, a quicker diagnosis can help doctors identify and treat disease complications earlier, such as heart issues associated with Friedreich's ataxia.
Scanning for known and novel diseases 'We've programmed the Nanopore device to hone in on the roughly 40 genes known to be involved in these disorders and to read through the long, repeated DNA sequences that cause disease,' he says. 'By unravelling the two strands of DNA and reading the repeated letter sequences (combinations of A, T, G or C), we can scan for abnormally long repeats within the patient's genes, which are the hallmarks of disease.' 'In the one test, we can search for every known disease-causing repeat expansion sequence, and potentially discover novel sequences likely to be involved in diseases that have not yet been described,' says Dr Deveson.
Upscaling to wider use in the next five years The team expects to see their new technology used in diagnostic practice within the next two to five years. One of the key steps towards that goal is to gain appropriate clinical accreditation for the method. Once accredited, the test will also transform research into genetic diseases, says Dr Gina Ravenscroft, a co-author of the study and a researcher working on rare disease genetics at the Harry Perkins Institute of Medical Research. 'Adult-onset genetic disorders haven't received as much research attention as those that appear in early life,' she says. 'By finding more people with these rare adult-onset diseases, and those who may be pre-symptomatic, we'll be able to learn more about a whole range of rare diseases through cohort studies, which would otherwise be hard to do.'
Research Report: "Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing"
Tiny biohybrid robots for intelligent drug delivery Beijing, China (SPX) Mar 07, 2022 A review paper by scientists at the Beijing Institute of Technology summarized recent advancements in use of intelligent biohybrid micro- and nanorobots for human medical applications. The new review paper, published on Feb. 10 in the journal Cyborg and Bionic Systems, provided an overview of how tiny robots with living parts are designed and fabricated to perform tasks such as effectively delivering drugs to body tissues. "These biohybrid micro- and nanorobots are being widely investigated in the ... read more
|
|||||||||||||
| The content herein, unless otherwise known to be public domain, are Copyright 1995-2026 - SpaceDaily. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |
del.icio.us
Digg
Reddit
Google
